Croda International Valuation
Is CRDA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Por debajo del valor justo
Muy por debajo del valor justo
Price-To-Earnings vs. similares
Price-To-Earnings vs. Industria
PM vs. Ratio Justo
Pronóstico de los analistas
Share Price vs Fair Value
What is the Fair Price of CRDA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Por debajo del valor justo: CRDA (£47.04) cotiza por encima de nuestra estimación de valor razonable (£44.65)
Muy por debajo del valor justo: CRDA cotiza por encima de nuestra estimación del valor razonable.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CRDA?
Other financial metrics that can be useful for relative valuation.
| What is CRDA's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | UK£6.35b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.1x |
| Enterprise Value/EBITDA | 21.3x |
| PEG Ratio | 2.4x |
Price to Earnings Ratio vs Peers
How does CRDA's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 24.4x | ||
JMAT Johnson Matthey | 18.4x | 21.3% | UK£3.3b |
VCT Victrex | 18.3x | 10.7% | UK£1.1b |
ELM Elementis | 38.9x | 29.0% | UK£867.8m |
TET Treatt | 22x | 14.4% | UK£240.9m |
CRDA Croda International | 37.1x | 15.2% | UK£6.3b |
Price-To-Earnings vs. similares: CRDA es caro según su Ratio Price-To-Earnings (33.6x) en comparación con la media de sus homólogos (17.9x).
Price to Earnings Ratio vs Industry
How does CRDA's PE Ratio compare vs other companies in the European Chemicals Industry?
Price-To-Earnings vs. Industria: CRDA es caro en función de su Ratio Price-To-Earnings (33.6x) en comparación con la media del sector European Chemicals (12.4x).
Price to Earnings Ratio vs Fair Ratio
What is CRDA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 37.1x |
| Fair PE Ratio | 20.1x |
PM vs. Ratio Justo: CRDA es caro en función de su Ratio Price-To-Earnings (33.6x) comparado con el Ratio Price-To-Earnings estimado (15.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | UK£45.48 | UK£49.73 +9.4% | 8.9% | UK£56.00 | UK£41.00 | n/a | 15 |
| Mar ’25 | UK£48.98 | UK£49.07 +0.2% | 9.1% | UK£56.00 | UK£41.00 | n/a | 15 |
| Feb ’25 | UK£49.67 | UK£49.65 -0.03% | 10.1% | UK£59.00 | UK£41.00 | n/a | 15 |
| Jan ’25 | UK£50.50 | UK£51.67 +2.3% | 10.0% | UK£63.00 | UK£44.00 | n/a | 15 |
| Dec ’24 | UK£44.80 | UK£52.53 +17.3% | 11.1% | UK£63.00 | UK£44.00 | n/a | 15 |
| Nov ’24 | UK£43.17 | UK£52.80 +22.3% | 11.0% | UK£63.00 | UK£44.00 | n/a | 15 |
| Oct ’24 | UK£49.15 | UK£62.13 +26.4% | 9.4% | UK£72.00 | UK£50.00 | n/a | 16 |
| Sep ’24 | UK£55.56 | UK£63.12 +13.6% | 8.8% | UK£72.00 | UK£50.00 | n/a | 17 |
| Aug ’24 | UK£58.06 | UK£63.71 +9.7% | 11.0% | UK£78.00 | UK£50.00 | n/a | 17 |
| Jul ’24 | UK£56.26 | UK£66.38 +18.0% | 11.9% | UK£78.00 | UK£50.00 | n/a | 16 |
| Jun ’24 | UK£61.40 | UK£76.41 +24.4% | 11.6% | UK£88.00 | UK£54.00 | n/a | 17 |
| May ’24 | UK£69.80 | UK£77.24 +10.7% | 11.2% | UK£88.00 | UK£54.00 | n/a | 17 |
| Apr ’24 | UK£64.98 | UK£77.18 +18.8% | 11.2% | UK£88.00 | UK£54.00 | UK£49.02 | 17 |
| Mar ’24 | UK£65.70 | UK£79.71 +21.3% | 12.7% | UK£104.45 | UK£54.00 | UK£48.98 | 19 |
| Feb ’24 | UK£69.54 | UK£79.97 +15.0% | 12.5% | UK£104.45 | UK£54.00 | UK£49.67 | 19 |
| Jan ’24 | UK£66.04 | UK£80.87 +22.4% | 12.6% | UK£104.45 | UK£54.00 | UK£50.50 | 19 |
| Dec ’23 | UK£69.22 | UK£80.81 +16.7% | 12.5% | UK£104.45 | UK£54.00 | UK£44.80 | 19 |
| Nov ’23 | UK£66.96 | UK£81.50 +21.7% | 13.1% | UK£104.45 | UK£54.00 | UK£43.17 | 19 |
| Oct ’23 | UK£64.46 | UK£82.23 +27.6% | 12.9% | UK£104.45 | UK£54.00 | UK£49.15 | 19 |
| Sep ’23 | UK£65.62 | UK£82.13 +25.2% | 13.9% | UK£104.45 | UK£54.00 | UK£55.56 | 19 |
| Aug ’23 | UK£74.16 | UK£81.94 +10.5% | 14.3% | UK£104.45 | UK£51.50 | UK£58.06 | 19 |
| Jul ’23 | UK£65.08 | UK£85.74 +31.7% | 13.6% | UK£101.00 | UK£51.50 | UK£56.26 | 18 |
| Jun ’23 | UK£67.58 | UK£85.79 +26.9% | 13.5% | UK£101.00 | UK£51.50 | UK£61.40 | 18 |
| May ’23 | UK£78.04 | UK£84.11 +7.8% | 16.5% | UK£100.00 | UK£46.95 | UK£69.80 | 20 |
| Apr ’23 | UK£78.60 | UK£84.11 +7.0% | 16.5% | UK£100.00 | UK£46.95 | UK£64.98 | 20 |
Pronóstico de los analistas: El precio objetivo es inferior a 20% superior al precio actual de la acción.